China Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Indu
Description
China Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Industry Forecast, 2023-2032
The China point-of-care glucose testing is primarily influenced by several significant factors. One of the major factors that is driving the market is presence of an aging population in China, coupled with an increase in awareness surrounding the management of diabetes. This has led to a greater emphasis on regular glucose testing, resulting in a significant increase in the number of patients and healthcare professionals opting for point-of-care testing solutions. These innovative devices offer instantaneous results, allowing for swift adjustments in treatment plans and lifestyle modifications. Moreover, surge in the prevalence of diabetes in China is contributing to the market's persistent growth. As the number of individuals diagnosed with diabetes continues to surge, the demand for efficient point-of-care glucose testing devices is increasing. This surge in demand is leading to the rapid expansion of the market. Furthermore, rise in the focus on early disease detection and management is driving the adoption of these devices in both clinical and home care settings.
On the other hand, the market's intricate dynamics are not devoid of obstacles. Regulatory obstacles and persistent presence in the healthcare sector represent one of the main constraints in the market growth. Acquiring the requisite approvals and certifications for point-of-care glucose testing products is expected to be a laborious and resource-intensive undertaking. These regulatory complexities frequently act as barriers for new participants, thereby increasing competition among established market players. However, the future of the market presents the potential for innovation, expansion, and evolution. The continuously broadening scope of applications for point-of-care glucose testing devices persistently reveals new opportunities. Apart from the conventional uses for type-1 and type-2 diabetes, these devices prove useful in various clinical situations. In addition, emergence of applications in monitoring gestational diabetes and perioperative care broadens the market's perspectives, providing avenues for growth that were previously concealed.
The China point-of-care glucose testing market is segmented into product type, application, and end user. Further, on the basis of product type, the market is segregated into lancing devices & strips and blood-glucose meter. Depending on application, it is bifurcated into type-1 diabetes and type-2 diabetes. By end user, the market is classified into hospitals & clinics, home care settings, and others. These market players are making significant investments in R&D to create devices that provide improved accuracy in readings, require smaller blood samples, and enable effortless transmission of data to mobile applications and healthcare providers. In addition, manufacturers are presently prioritizing cost-effective product development while ensuring the accessibility of their devices. A common approach utilized to cater to various customer segments involves offering a variety of pricing tiers and subscription models for connected services.
The Porter’s five forces analysis analyzes the competitive scenario of the China point-of-care glucose testing market and role of each stakeholder. These forces include the bargaining power of suppliers, bargaining power of buyers, threat of new entrants, threat of substitutes, and competitive rivalry.The threat of new entrants poses a complex challenge within the market. The existence of regulatory obstacles and the requirement for significant financial investments establish formidable obstacles for aspiring entrants. The complexity is compounded by significant bargaining power of suppliers. Suppliers possess considerable influence due to the market's reliance on cutting-edge technology and superior components, rendering them indispensable. Consequently, this intricate scenario gives rise to a multifaceted interplay of negotiation and collaboration.
The bargaining power of buyers is a persistent reminder of the price sensitivity of the Chinese market. The market is characterized by economic diversity, and buyers, comprising healthcare institutions and individual consumers, wield significant influence. The threat of substitute poses a significant risk, as it introduces an element of unpredictability. With the continuous advancement of technology, there is a possibility of new glucose testing methods emerging, which potentially challenge the effectiveness of conventional devices. Therefore, it is imperative for market participants to maintain a state of constant vigilance in their pursuit of innovation to maintain a competitive edge.
The competitive rivalry is the driving force of the market. As established players compete for dominance and new entrants endeavor to establish their presence, competition is intense and constantly evolving. The market's complex dynamics unfold within this competitive landscape. A thorough comprehension of the market would be inadequate without consideration of its internal strengths and weaknesses, and external opportunities and threats it confronts. This consideration, similar to a SWOT analysis, reveals some aspects of the China point-of-care glucose testing market.
The market's strengths are rooted in its unwavering commitment to innovation and adaptability. Its capacity to embrace emerging technologies, address evolving healthcare demands, and expand its range of applications positions it as a dynamic and influential force. Furthermore, its strategic emphasis on patient-centric solutions further enhances its robustness. Nevertheless, this dynamic market harbors inherent weaknesses. The intricate regulatory framework, characterized by protracted approval procedures, has the potential to impede innovation and hinder market entry. In addition, economic fluctuations in China, which serve as a backdrop to the market's narrative, introduce an element of unpredictability.
Opportunities manifest themselves within this market, including increase in utilization of point-of-care glucose testing devices, coupled with rise in the incidence of diabetes, present avenues for market expansion. In addition, increase in emphasis on home care environments and the empowerment of patients give rise to novel prospects for growth. However, the market is not devoid of its threats. price sensitivity and resource constraints pose a substantial challenge. Moreover, rise in threat of emerging technologies capable of disrupting the current market further exacerbates the situation. In conclusion, the China point-of-care glucose testing market is expected to be characterized as a multifaceted landscape of innovation and intricacy. It is a market propelled by unwavering commitment to accuracy, intricacies of regulatory frameworks, and vast potential for groundbreaking advancements.
Key players operating in the China point-of-care glucose testing market include Roche, Abbott, Siemens Healthcare, Johnson & Johnson, Medtronic, A. Menarini Diagnostics, Biosense Medical, Sannuo Medical Technologies, Optimum Diagnostics, and Sysmex Biomedical.
Key Benefits For Stakeholders
Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
Analyze the key strategies adopted by major market players in China point-of-care glucose testing market.
Assess and rank the top factors that are expected to affect the growth of China point-of-care glucose testing market.
Top Player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the China point-of-care glucose testing market segmentation assists to determine the prevailing market opportunities.
Identify key investment pockets for various offerings in the market.
Product Benchmarking / Product specification and applications
Upcoming/New Entrant by Regions
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis
Key Market Segments
By Product Type
Lancing Devices and Strips
Blood-Glucose Meter
Type
Lifescan OneTouch Ultra and Lifescan OneTouch Verio
Accu-Chek Aviva Plus and Accuchek
Freestyle Lite and Freestyle Precission Neo
Contour Next
Others
By Application
Type-1 Diabetes
Type-2 Diabetes
By End User
Hospitals and Clinics
Home Care Settings
Others
Key Market Players
Roche
Abbott
Siemens Healthcare
Johnson & Johnson
Medtronic
A. Menarini Diagnostics
Biosense Medical
Sannuo Medical Technologies
Optimum Diagnostics
Sysmex Biomedical
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
88 Pages
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits to the Stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Impacting Factors
- 3.2.2. Top Investment Pockets
- 3.3. Porter’s Five Forces Analysis
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: CHINA POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE
- 4.1. Overview
- 4.1.1. Market Size and Forecast, By Product Type
- 4.2. Lancing Devices and Strips
- 4.3. Blood-Glucose Meter
- CHAPTER 5: CHINA POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION
- 5.1. Overview
- 5.1.1. Market Size and Forecast, By Application
- 5.2. Type-1 Diabetes
- 5.3. Type-2 Diabetes
- CHAPTER 6: CHINA POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER
- 6.1. Overview
- 6.1.1. Market Size and Forecast, By End User
- 6.2. Hospitals and Clinics
- 6.3. Home Care Settings
- 6.4. Others
- CHAPTER 7: COMPETITIVE LANDSCAPE
- 7.1. Introduction
- 7.2. Top winning strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top player positioning, 2022
- CHAPTER 8: COMPANY PROFILES
- 8.1. Roche
- 8.1.1. Company overview
- 8.1.2. Key Executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
- 8.1.7. Key strategic moves and developments
- 8.2. Abbott
- 8.2.1. Company overview
- 8.2.2. Key Executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
- 8.2.7. Key strategic moves and developments
- 8.3. Siemens Healthcare
- 8.3.1. Company overview
- 8.3.2. Key Executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
- 8.3.7. Key strategic moves and developments
- 8.4. Johnson & Johnson
- 8.4.1. Company overview
- 8.4.2. Key Executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
- 8.4.7. Key strategic moves and developments
- 8.5. Medtronic
- 8.5.1. Company overview
- 8.5.2. Key Executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
- 8.5.7. Key strategic moves and developments
- 8.6. A. Menarini Diagnostics
- 8.6.1. Company overview
- 8.6.2. Key Executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
- 8.6.7. Key strategic moves and developments
- 8.7. Biosense Medical
- 8.7.1. Company overview
- 8.7.2. Key Executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
- 8.7.7. Key strategic moves and developments
- 8.8. Sannuo Medical Technologies
- 8.8.1. Company overview
- 8.8.2. Key Executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
- 8.8.7. Key strategic moves and developments
- 8.9. Optimum Diagnostics
- 8.9.1. Company overview
- 8.9.2. Key Executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
- 8.9.7. Key strategic moves and developments
- 8.10. Sysmex Biomedical
- 8.10.1. Company overview
- 8.10.2. Key Executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Business performance
- 8.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. CHINA POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
- TABLE 02. CHINA POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 03. CHINA POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 04. ROCHE: KEY EXECUTIVES
- TABLE 05. ROCHE: COMPANY SNAPSHOT
- TABLE 06. ROCHE: OPERATING SEGMENTS
- TABLE 07. ROCHE: PRODUCT PORTFOLIO
- TABLE 08. ROCHE: KEY STRATERGIES
- TABLE 09. ABBOTT: KEY EXECUTIVES
- TABLE 10. ABBOTT: COMPANY SNAPSHOT
- TABLE 11. ABBOTT: OPERATING SEGMENTS
- TABLE 12. ABBOTT: PRODUCT PORTFOLIO
- TABLE 13. ABBOTT: KEY STRATERGIES
- TABLE 14. SIEMENS HEALTHCARE: KEY EXECUTIVES
- TABLE 15. SIEMENS HEALTHCARE: COMPANY SNAPSHOT
- TABLE 16. SIEMENS HEALTHCARE: OPERATING SEGMENTS
- TABLE 17. SIEMENS HEALTHCARE: PRODUCT PORTFOLIO
- TABLE 18. SIEMENS HEALTHCARE: KEY STRATERGIES
- TABLE 19. JOHNSON & JOHNSON: KEY EXECUTIVES
- TABLE 20. JOHNSON & JOHNSON: COMPANY SNAPSHOT
- TABLE 21. JOHNSON & JOHNSON: OPERATING SEGMENTS
- TABLE 22. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
- TABLE 23. JOHNSON & JOHNSON: KEY STRATERGIES
- TABLE 24. MEDTRONIC: KEY EXECUTIVES
- TABLE 25. MEDTRONIC: COMPANY SNAPSHOT
- TABLE 26. MEDTRONIC: OPERATING SEGMENTS
- TABLE 27. MEDTRONIC: PRODUCT PORTFOLIO
- TABLE 28. MEDTRONIC: KEY STRATERGIES
- TABLE 29. A. MENARINI DIAGNOSTICS: KEY EXECUTIVES
- TABLE 30. A. MENARINI DIAGNOSTICS: COMPANY SNAPSHOT
- TABLE 31. A. MENARINI DIAGNOSTICS: OPERATING SEGMENTS
- TABLE 32. A. MENARINI DIAGNOSTICS: PRODUCT PORTFOLIO
- TABLE 33. A. MENARINI DIAGNOSTICS: KEY STRATERGIES
- TABLE 34. BIOSENSE MEDICAL: KEY EXECUTIVES
- TABLE 35. BIOSENSE MEDICAL: COMPANY SNAPSHOT
- TABLE 36. BIOSENSE MEDICAL: OPERATING SEGMENTS
- TABLE 37. BIOSENSE MEDICAL: PRODUCT PORTFOLIO
- TABLE 38. BIOSENSE MEDICAL: KEY STRATERGIES
- TABLE 39. SANNUO MEDICAL TECHNOLOGIES: KEY EXECUTIVES
- TABLE 40. SANNUO MEDICAL TECHNOLOGIES: COMPANY SNAPSHOT
- TABLE 41. SANNUO MEDICAL TECHNOLOGIES: OPERATING SEGMENTS
- TABLE 42. SANNUO MEDICAL TECHNOLOGIES: PRODUCT PORTFOLIO
- TABLE 43. SANNUO MEDICAL TECHNOLOGIES: KEY STRATERGIES
- TABLE 44. OPTIMUM DIAGNOSTICS: KEY EXECUTIVES
- TABLE 45. OPTIMUM DIAGNOSTICS: COMPANY SNAPSHOT
- TABLE 46. OPTIMUM DIAGNOSTICS: OPERATING SEGMENTS
- TABLE 47. OPTIMUM DIAGNOSTICS: PRODUCT PORTFOLIO
- TABLE 48. OPTIMUM DIAGNOSTICS: KEY STRATERGIES
- TABLE 49. SYSMEX BIOMEDICAL: KEY EXECUTIVES
- TABLE 50. SYSMEX BIOMEDICAL: COMPANY SNAPSHOT
- TABLE 51. SYSMEX BIOMEDICAL: OPERATING SEGMENTS
- TABLE 52. SYSMEX BIOMEDICAL: PRODUCT PORTFOLIO
- TABLE 53. SYSMEX BIOMEDICAL: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. CHINA POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF CHINA POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN CHINA POINT-OF-CARE GLUCOSE TESTING MARKET (2023-2032)
- FIGURE 04. PORTER FIVE-1
- FIGURE 05. PORTER FIVE-2
- FIGURE 06. PORTER FIVE-3
- FIGURE 07. PORTER FIVE-4
- FIGURE 08. PORTER FIVE-5
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: CHINA POINT-OF-CARE GLUCOSE TESTING MARKET
- FIGURE 10. CHINA POINT-OF-CARE GLUCOSE TESTING MARKET,BY PRODUCT TYPE, 2022 ($MILLION)
- FIGURE 11. CHINA POINT-OF-CARE GLUCOSE TESTING MARKET,BY APPLICATION, 2022 ($MILLION)
- FIGURE 12. CHINA POINT-OF-CARE GLUCOSE TESTING MARKET,BY END USER, 2022 ($MILLION)
- FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 17. COMPETITIVE DASHBOARD
- FIGURE 18. COMPETITIVE HEATMAP: CHINA POINT-OF-CARE GLUCOSE TESTING MARKET
- FIGURE 19. TOP PLAYER POSITIONING, 2022
- FIGURE 20. ROCHE: NET SALES, 2020-2022* ($MILLION)
- FIGURE 21. ROCHE: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 22. ROCHE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 23. ABBOTT: NET SALES, 2020-2022* ($MILLION)
- FIGURE 24. ABBOTT: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 25. ABBOTT: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 26. SIEMENS HEALTHCARE: NET SALES, 2020-2022* ($MILLION)
- FIGURE 27. SIEMENS HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 28. SIEMENS HEALTHCARE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 29. JOHNSON & JOHNSON: NET SALES, 2020-2022* ($MILLION)
- FIGURE 30. JOHNSON & JOHNSON: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 31. JOHNSON & JOHNSON: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 32. MEDTRONIC: NET SALES, 2020-2022* ($MILLION)
- FIGURE 33. MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 34. MEDTRONIC: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 35. A. MENARINI DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)
- FIGURE 36. A. MENARINI DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 37. A. MENARINI DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 38. BIOSENSE MEDICAL: NET SALES, 2020-2022* ($MILLION)
- FIGURE 39. BIOSENSE MEDICAL: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 40. BIOSENSE MEDICAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 41. SANNUO MEDICAL TECHNOLOGIES: NET SALES, 2020-2022* ($MILLION)
- FIGURE 42. SANNUO MEDICAL TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 43. SANNUO MEDICAL TECHNOLOGIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 44. OPTIMUM DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)
- FIGURE 45. OPTIMUM DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 46. OPTIMUM DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 47. SYSMEX BIOMEDICAL: NET SALES, 2020-2022* ($MILLION)
- FIGURE 48. SYSMEX BIOMEDICAL: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 49. SYSMEX BIOMEDICAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

